Deutsche Bank AG Sells 512,069 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Deutsche Bank AG has reduced its stake in ADMA Biologics Inc by 13.2%, now holding approximately 3.36 million shares valued at $66.74 million.
• Insider selling has been prominent, with Director Lawrence P. Guiheen and Director Steve Elms selling significant shares, reducing their positions by 17.42% and 69.04%, respectively.
• ADMA Biologics has been upgraded to a “strong-buy” rating by Raymond James Financial, increasing their price target from $25.00 to $32.00.

Deutsche Bank AG trimmed its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 13.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,363,639 shares of the biotechnology company's stock after selling 512,069 shares during the period. Deutsche Bank AG owned approximately 1.42% of ADMA Biologics worth $66,735,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in ADMA Biologics by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,462,005 shares of the biotechnology company's stock worth $48,846,000 after buying an additional 21,711 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in ADMA Biologics by 24.3% during the first quarter. PNC Financial Services Group Inc. now owns 23,325 shares of the biotechnology company's stock worth $463,000 after buying an additional 4,553 shares in the last quarter. Alberta Investment Management Corp grew its stake in ADMA Biologics by 17.8% during the first quarter. Alberta Investment Management Corp now owns 294,250 shares of the biotechnology company's stock worth $5,838,000 after buying an additional 44,557 shares in the last quarter. Natixis Advisors LLC grew its stake in ADMA Biologics by 26.0% during the first quarter. Natixis Advisors LLC now owns 36,723 shares of the biotechnology company's stock worth $729,000 after buying an additional 7,570 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $52,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of research analyst reports. Raymond James Financial raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock worth $9,644,269 in the last quarter. 3.50% of the stock is owned by insiders.

ADMA Biologics Price Performance

Shares of ADMA traded up $0.02 during mid-day trading on Friday, reaching $16.99. The company had a trading volume of 3,108,545 shares, compared to its average volume of 3,534,720. The company's 50 day simple moving average is $18.29 and its 200 day simple moving average is $18.84. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of 19.76 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm's quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company posted $0.13 EPS. Analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.